Brief: EMA's CHMP Recommends Granting A Marketing Authorisation For Cenrifki (Tolebrutinib)

Soleno Therapeutics

24/04/2026 11:07

April 24 (Reuters) - EMA's CHMP

EMA'S CHMP: RECOMMENDED GRANTING A MARKETING AUTHORISATION FOR CENRIFKI (TOLEBRUTINIB)

EMA'S CHMP: RECOMMENDED GRANTING A MARKETING AUTHORISATION FOR THE GENE THERAPY MEDICINE ITVISMA (ONASEMNOGENE ABEPARVOVEC)

EMA'S CHMP: ADOPTED A POSITIVE OPINION FOR REDEMPLO (PLOZASIRAN)

EMA'S CHMP: PALBOCICLIB VIATRIS (PALBOCICLIB), RECEIVED A POSITIVE OPINION FOR THE TREATMENT OF BREAST CANCER

EMA'S CHMP: FINALISED ASSESSMENT OF APPLICATION TO EXTEND USE OF OPDUALAG TO INCLUDE THE TREATMENT OF ADVANCED MELANOMA

EMA'S CHMP: EMA DID NOT RECOMMEND EXTENSION OF USE OF OPDUALAG, AGREED RELEVANT DATA SUBMITTED BE INCLUDED IN MEDICINE’S PRODUCT INFORMATION

EMA: CHMP RECOMMENDED EXTENSIONS OF INDICATION FOR NINE MEDICINES INCLUDING COMIRNATY

 ((Reuters.Briefs@thomsonreuters.com;))